methyl 1-isopropyl-1H-indole-6-carboxylate | 202745-76-4

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: methyl 1-isopropyl-1H-indole-6-carboxylate
• 英文别名: 6-carbomethoxy-1-(2-propyl)-indole；methyl 1-isopropylindole-6-carboxylate；methyl 1-propan-2-ylindole-6-carboxylate
• CAS: 202745-76-4
• 化学式: C₁₃H₁₅NO₂
• 分子量: 217.268
• InChiKey: QFHTWTKDRUFTJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  31.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  胍 、 methyl 1-isopropyl-1H-indole-6-carboxylate 反应 0.08h， 生成 N-carbamimidoyl-1-propan-2-ylindole-6-carboxamide
  参考文献：
  名称：

  N-（氨基亚氨基甲基）-1H-吲哚羧酰胺衍生物作为Na + / H +交换抑制剂的合成及其生物活性。

  摘要：

  合成了一系列的N-（氨基亚氨基甲基）-1H-吲哚羧酰胺衍生物，并测定了它们对Na + / H +交换剂的抑制能力。吲哚环系统2到7位羰基胍基团的变化表明，在2位取代可以最有效地提高Na + / H +交换子的抑制活性。这导致合成和评估了一系列广泛的N-（氨基亚氨基甲基）-1H-吲哚-2-羧酰胺衍生物。在吲哚环系统的1-位具有烷基或取代的烷基的衍生物显示出更高水平的体外活性。N-（氨基亚氨基甲基）-1-（2-苯乙基）-1H-吲哚-2-羧酰胺（49）具有最强的活性。

  DOI：

  10.1248/cpb.47.1538
• 作为产物：
  描述：

  4-carbomethoxy-2-(N-2-propylamino)phenylacetaldehyde dimethylacetal 在 盐酸 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 生成 methyl 1-isopropyl-1H-indole-6-carboxylate
  参考文献：
  名称：

  Substituted pyrroles

  摘要：

  式##STR1##中的化合物，其中R.sup.1和R.sup.1'分别独立地是烷基、芳基、烯基或炔基；R.sup.2和R.sup.2'独立地是氢或烷基；R.sup.4、R.sup.5、R.sup.6和R.sup.7每个独立地是##STR2## CH.sub.2 OR.sup.10、CHO、CH.sub.2 NR.sup.11 R.sup.12、氢、卤素、氰基、烷基、羟基、烷氧基、芳氧基、卤代烷基、硝基、氨基、酰胺基、芳基氧基、单烷基氨基、双烷基氨基、烷基硫基、烷基砜基或烷基砜酰基，前提是R.sup.4、R.sup.5、R.sup.6或R.sup.7中至少有一个是氰基，##STR3## CH.sub.2 OR.sup.10、CH.sub.2 NR.sup.11 R.sup.12或CHO；R.sup.8是烷基、芳基烷基或芳基；R.sup.10是氢、烷基、芳基烷基或芳基；R.sup.11和R.sup.12独立地是氢、烷基、芳基、芳基烷基或酰基；X和Y中的一个表示O，另一个表示O、S、(H,OH)或(H,H)；以及具有公认的药用价值的酸性化合物或碱性化合物的药物可接受的前药或盐的抗增殖剂在癌症治疗中有用。

  公开号：

  US05856517A1

文献信息

• Rh(<scp>iii</scp>)-Catalyzed regioselective C4 alkylation of indoles with allylic alcohols: direct access to β-indolyl ketones
  作者：Changduo Pan、Gao Huang、Yujia Shan、Yiting Li、Jin-Tao Yu

  DOI：10.1039/d0ob00396d

  日期：——

  A Rh(iii)-catalyzed and weak coordination carbonyl guided direct C4 alkylation of indoles with allylic alcohols was developed with excellent regioselectivity. This reaction was conducted under mild conditions, leading to a variety of β-indolyl ketones with good functional group tolerance in moderate to good yields.

  发展了Rh（iii）催化和弱配位羰基引导的吲哚与烯丙基醇的直接C4烷基化，具有出色的区域选择性。该反应在温和的条件下进行，从而以中等至良好的产率产生了各种具有良好的官能团耐受性的β-吲哚基酮。
• Substituted pyrroles compositions
  申请人：Hoffmann-La Roche Inc.

  公开号：US06030994A1

  公开（公告）日：2000-02-29

  Compounds of the formula ##STR1## wherein R.sup.1, R.sup.1 ', R.sup.2, R.sup.2 ' R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as described herein; as well as pharmaceutically acceptable prodrugs or salts of acidic compounds of formula I with bases and or basic compounds of formula I with acids are antiproliferative agents useful in the treatment of cancer.

  式为##STR1##的化合物，其中R.sup.1，R.sup.1'，R.sup.2，R.sup.2'，R.sup.4，R.sup.5，R.sup.6和R.sup.7如本文所述；以及公认为适用于药用的化合物I的酸性衍生物的前药或与酸性化合物I的碱和/或碱性化合物I的盐是抗增殖剂，可用于治疗癌症。
• Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
  申请人：Coburn A. Craig

  公开号：US20070021454A1

  公开（公告）日：2007-01-25

  The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式（I）及其互变异构体的螺环吡啶化合物，这些化合物是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶参与的疾病，如阿尔茨海默病方面是有用的。本发明还涉及包括这些化合物的制药组合物以及在治疗β-分泌酶酶参与的这些疾病中使用这些化合物和组合物的用途。
• Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
  申请人：Merck, Sharp & Dohme Corp.

  公开号：US08211904B2

  公开（公告）日：2012-07-03

  The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及公式(I)的螺环吡啶化合物及其互变异构体，其为β-分泌酶酶抑制剂，可用于治疗涉及β-分泌酶酶的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的制药组合物以及将这些化合物和组合物用于治疗涉及β-分泌酶酶的疾病的用途。
• NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE
  申请人：Peters Dan

  公开号：US20120003153A1

  公开（公告）日：2012-01-05

  This invention relates to novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及新型吲哚-噁唑-哌嗪-壬烷衍生物及其在制药组合物制备中的应用。本发明的化合物被发现是乙酰胆碱受体的胆碱能配体，同时也是单胺类受体和转运体的调节剂。由于其药理学特性，本发明的化合物可能对治疗与中枢神经系统（CNS）和外周神经系统（PNS）的胆碱能系统相关的疾病或紊乱、平滑肌收缩相关的疾病或紊乱、内分泌疾病或紊乱、神经退行性疾病或紊乱、炎症相关的疾病或紊乱、疼痛以及由于滥用化学物质而导致的戒断症状可能有用。